Login
Companies $CCCC
$2.63 -$0.02 (0.75%) After hours
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

c4therapeutics.com

What Do They Do?

Develops small-molecule medicines designed to break down disease-causing proteins for cancer and inflammatory and neurological diseases.

How Do They Make Money?

C4T earns revenue from research collaborations and licenses through upfront fees, cost reimbursements, option and milestone payments, and royalties on licensed-product sales. Collaboration revenue is earned over the agreement's work period, while a distinct upfront license fee is earned when the partner can use the rights.

FY2025 revenue

Who Are Their Customers?

Collaborators such as Merck KGaA and Roche work with the company on drug discovery; Betta Pharma licenses and develops CFT8919 in Greater China.

Do Revenues Turn Into Profits?

No. It lost $105M in FY2025.

Operating income, FY2025
−321% of revenue
▲ +4% (Loss) vs FY2024 (−$119.6M, −336%)
Net income, FY2025
−292% of revenue
▲ 0% (Loss) vs FY2024 (−$105.3M, −296%)
Free cash flow, FY2025
−276% of revenue
▼ −52% (Loss) vs FY2024 (−$65.3M, −184%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −25%
vs $11.2M in Q3 FY2025
Net income
▲ +32% (Loss)
vs −$32.2M in Q3 FY2025
  • Apr 9, 2026 C4T licensed two oncology degrader-antibody conjugate targets to Roche Roche agreed to pay $20.0 million upfront and cover development, regulatory, manufacturing, and commercialization costs; C4T may also receive milestones and royalties.

Shrinking. Revenue fell 21% in 4 years, from $45.8M in FY2021 to $35.9M in FY2025, about 6% a year.

Pipeline focus The older report listed oncology candidates for multiple myeloma and lymphoma, synovial sarcoma, BRAF-mutant tumors, and EGFR-mutant lung cancer. The latest report centers the clinical pipeline on multiple myeloma and EGFR-mutant lung cancer while describing discovery work in inflammation, neuroinflammation, and neurodegeneration.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support